⚡ Live Signal Feed
122 signals · Ranked by priority · Clinical research + community sentiment
Priority = sentiment strength × evidence quality (max 99) · Community signals capped at "Moderate"
122
Total Signals
All sources combined
100
🔬 Clinical/Research
Peer-reviewed + gov sources
22
🗣 Community
Reddit & forum discussions
44
🇺🇸 US Signals
US-sourced intelligence
34
🇨🇦 Canada Signals
Canada-specific coverage
5 Signals · Sorted by Priority80–99 = high impact · 60–79 = notable · below = monitoring
🌎 Both▲ Nutrition↑ PositivePeer-Reviewed
Bayer's July 2025 launch of Supradyn Naturals Ginseng marks a strategic entry into men-specific supplementation, claiming 10x antioxidant power in a vegetarian, sugar-free format. This represents major pharma investment in gender-targeted nutrition.
99
Priority
High
🇨🇦 Canada▲ Nutrition↑ PositivePeer-Reviewed
Near-universal supplement adoption among Canadian adults demonstrates VMS products are a core pillar of Canadian wellness routines. This high baseline usage suggests a mature market with strong consumer engagement.
96
Priority
High
🇺🇸 US▲ Nutrition↑ PositiveModerate
GNC Holdings introduced Mega Men Ultra Testosterone in June 2023, a science-backed formulation designed to optimize testosterone levels using proprietary delivery technology. This signals continued industry focus on hormone optimization for men's health.
90
Priority
High
🇺🇸 US▲ Nutrition↓ Risk SignalModerate
After four decades of tracking supplement research, Men's Health magazine cautions consumers that many product claims are overstated, emphasizing need for evidence-based purchasing. This underscores persistent gap between marketing and scientific evidence.
76
Priority
Notable
🇨🇦 Canada▲ NutritionModerate
Following its ZAVA acquisition, Hims & Hers will enter Canada in 2026, timing expansion with generic semaglutide availability for obesity treatment. This signals growing integration of digital health platforms with men's supplement offerings.
55
Priority
Monitor